Close Menu

NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market Tuesday that its revenues dropped 14 percent in the first quarter as higher product sales were offset by lower research revenues year over year.

The Lexington, Massachusetts-based molecular diagnostics firm reported total revenues of $941,000, down from $1.1 million in Q1 2016 and well below analysts' average expectation of $2 million.

Its product revenues were $631,000 versus $437,000 in Q1 2016, while its research revenues were $310,000 compared to $659,000 a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.